drug
as of 2026-07-01glycine
Glycine
MeSH D005998
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Yale University
8 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
8
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
NCT01720316Phase 2Completed
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
NCT00338598Phase 2Completed
Glycine vs Placebo for the Schizophrenia Prodrome
NCT00291226Phase 2, Phase 3Completed
Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia
NCT00575848Phase 1Terminated
Glycine and D-Cycloserine in Schizophrenia
NCT00000372Phase 3Withdrawn
Glycine Treatment of Prodromal Symptoms
NCT00268749Phase 2Completed
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
NCT00222235Phase 2, Phase 3Completed
Glycine to Treat Psychotic Disorders in Children
NCT00005658Phase 2Completed
KOLs & investigators
7
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
KOL
Donald C. Goff, MD
personKOL score 8
Scott W. Woods, MD
personKOL score 8
William T Carpenter, MD
personKOL score 5
Deborah L Levy, PhD
personKOL score —